Target Name: VWA8
NCBI ID: G23078
Other Name(s): P7BP2 | von Willebrand factor A domain-containing protein 8 | Von Willebrand factor A domain-containing protein 8 precursor (isoform b) | VWA8 variant 1 | KIAA0564 | Von Willebrand factor A domain containing 8, transcript variant 1 | VWA8_HUMAN | von Willebrand factor A domain containing 8 | PEX7-binding protein 2 | Pex7p-binding protein 2

VWA8: A Potential Drug Target for Cancer

VWA8 (P7BP2), a protein located in the endoplasmic reticulum (ER), has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and subcellular localization in the ER make it an attractive target for small molecules and antibodies.

The ER is a transmembrane system, which spans the length of the cell and functions as a sorting station for various proteins. It is responsible for importing and processing proteins from the cytoplasm into the cell surface. The ER is also the site of protein degradation and modulation, which makes it a crucial hub for the regulation of cellular processes.

VWA8 is a member of the P7 family of proteins, which are involved in the ER retention and localization of various proteins. P7 proteins localize to the ER through their C-terminus, which contains a unique acidic amino acid sequence known as P7 conserved domain (P7 domain). The P7 domain is involved in the formation of a hydrophobic core, which draws water into the ER and facilitates protein recruitment.

VWA8 is a 21 kDa protein that localizes to the end of the long arm (L) of the P7 protein. It has a unique structure, with a long N-terminus and a C-terminus that is involved in the formation of a hydrophobic core . VWA8 is also known as P7BP2 due to its interaction with the P7 protein. The P7BP2 domain is responsible for the protein's stability and localization to the ER.

In cancer, the P7BP2 protein has been shown to be overexpressed or mutated in various tissues, including breast, ovarian, and prostate cancer cells. Overexpression of VWA8 has been shown to promote the growth and survival of cancer cells, while mutations in the P7BP2 domain have been linked to the development of cancer stem cells and the failure of cancer therapies.

The potential drug targets for VWA8 include the inhibition of its phosphorylation at its Serine-29 residue, which is known to play a role in the regulation of protein stability and localization. Additionally, the inhibition of the interaction between VWA8 and the P7 protein has been shown to be a potential strategy for cancer treatment.

In conclusion, VWA8 is a protein with great potential as a drug target and biomarker for various diseases, including cancer. Its unique localization to the ER and its involvement in the regulation of protein stability and localization make it an attractive target for small molecules and antibodies . Further studies are needed to fully understand the role of VWA8 in disease progression and the development of new cancer therapies.

Protein Name: Von Willebrand Factor A Domain Containing 8

Functions: Exhibits ATPase activity in vitro

More Common Targets

VWC2 | VWC2L | VWCE | VWDE | VWF | VXN | WAC | WAC-AS1 | WAKMAR1 | WAKMAR2 | WAPL | WARS1 | WARS2 | WARS2-AS1 | WAS | WASF1 | WASF2 | WASF3 | WASF4P | WASF5P | WASH complex | WASH2P | WASH3P | WASH4P | WASH5P | WASH6P | WASH7P | WASH8P | WASHC1 | WASHC2A | WASHC2C | WASHC3 | WASHC4 | WASHC5 | WASIR1 | WASL | WAVE1 complex | WBP1 | WBP11 | WBP11P1 | WBP1L | WBP2 | WBP2NL | WBP4 | WDCP | WDFY1 | WDFY2 | WDFY3 | WDFY3-AS2 | WDFY4 | WDHD1 | WDPCP | WDR1 | WDR11 | WDR11-DT | WDR12 | WDR13 | WDR17 | WDR18 | WDR19 | WDR20 | WDR24 | WDR25 | WDR26 | WDR27 | WDR3 | WDR31 | WDR33 | WDR35 | WDR35-DT | WDR36 | WDR37 | WDR38 | WDR4 | WDR41 | WDR43 | WDR44 | WDR45 | WDR45B | WDR46 | WDR47 | WDR48 | WDR49 | WDR5 | WDR53 | WDR54 | WDR55 | WDR59 | WDR5B | WDR6 | WDR62 | WDR64 | WDR7 | WDR70 | WDR72 | WDR73 | WDR74 | WDR75 | WDR76 | WDR77